Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Agenus Inc. announced the granting of inducement awards to three new executives as part of their appointments [1] - The awards are part of Agenus' 2015 Inducement Equity Plan and comply with Nasdaq Listing Rule 5635(c)(4) [1] Summary by Executive - Nils Eckardt: Received options to purchase 100,000 shares with a 10-year term, an exercise price based on the closing price on February 1, 2024, and vesting over four years in equal annual installments, along with 50,000 restricted stock units vesting over three years [2] - Kent Barnes: Awarded options to purchase 100,000 shares with a 10-year term, an exercise price based on the closing price on April 1, 2024, and vesting over four years in equal annual installments, plus 100,000 restricted stock units vesting over three years [3] - Brian Greenblatt: Granted options to purchase 75,000 shares with a 10-year term, an exercise price based on the closing price on April 1, 2024, and vesting over four years in equal annual installments, along with 60,000 restricted stock units vesting over three years [4] Company Overview - Agenus is a leading immuno-oncology company focused on cancer and infectious diseases, with a comprehensive pipeline of immunological agents [5] - The company's mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, utilizing a broad range of antibody therapeutics, adoptive cell therapies, and adjuvants [5] - Agenus is headquartered in Lexington, MA, and provides information important to investors on its website and social media channels [5]